+41 91 682 20 40 info@elixi-int.com


We are a Swiss pharmaceutical wholesaler, specialized in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.

Here in ELIXI we consider fast delivery of life-saving medicines as a basic but mandatory human value.



As a pharmaceutical wholesaler, working directly with pharma manufactures, medicine distributors, hospitals and clinics, we comply with the newest Standard Operating Procedures (SOPs), which guide our professional team step-by-step in all of ELIXI’s activities ensuring the highest quality standards required by the pharma world.

> Read more



We deliver pharma products from Switzerland and from all over the world.

Our team in ELIXI International has a solid experience in the distribution of medical products.

History has taught us to prioritize the urgency that lays behind the need of supplying a drug in the fastest possible way. Here in ELIXI we consider fast delivery as a basic but mandatory human value. In order to achieve this goal, we developed a simple but qualified process made of synergies with long lasting partners who, like us, believe in people and not in machines.



Pfizer’s Mylotarg approved to treat a certain subset of patients with acute myeloid leukaemia (AML).

On 22 February 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing…

read more

FDA expands approval of Blincyto for treatment of a type of leukemia in patients who have a certain risk factor for relapse

The U.S. Food and Drug Administration granted accelerated approval to Blincyto (blinatumomab) to treat adults and children with B-cell precursor…

read more

FDA approves osimertinib (Tagrisso) for first-line treatment of metastatic NSCLC with most common EGFR mutations

AstraZeneca’s Tagrisso has been approved in the US as a first-line treatment for patients with metastatic non-small-cell lung cancer whose…

read more

FDA approves Crysvita (burosumab), first therapy for rare inherited form of rickets, x-linked hypophosphatemia

The U.S. Food and Drug Administration today approved Crysvita (burosumab), the first drug approved to treat adults and children ages…

read more

FDA approves Tavalisse ( fostamatinib disodium hexahydrate ) for the treatment of thrombocytopenia

Rigel Pharmaceuticals has obtained its first FDA approval, with a green light to market Tavalisse for the treatment of thrombocytopenia…

read more

Steglujan (ertugliflozin / sitagliptin) approved by EMA for the treatment of type 2 diabetes

Steglujan is a medicine used to control blood glucose (sugar) levels in adults with type 2 diabetes. It is used…

read more

Novartis’ Afinitor Disperz wins new TSC-related approval

Novartis’ Afinitor Disperz has become the first medicine to be specifically approved by US regulators to treat patients aged two…

read more

Teva Announces the Launch of a Generic Version of Lialda (mesalamine) in the United States

On  Mar. 26, 2018,  Teva Pharmaceutical Industries Ltd has announced the launch of a generic version of Lialda (mesalamine) delayed-release tablets,…

read more

FDA Approves Ilumya for the the treatment of Moderate-to-Severe Plaque Psoriasis

Officials with the FDA have approved tildrakizumab-asmn, (Ilumya, Sun Pharma) for treating adults with moderate-to-severe plaque psoriasis, according to the…

read more

FDA approves rucaparib for maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer

On April 6, 2018, the Food and Drug Administration approved rucaparib (Rubraca®, Clovis Oncology Inc.), a poly ADP-ribose polymerase (PARP)…

read more

AstraZeneca receives EU approval of Fasenra for severe eosinophilic asthma

Fasenra is an asthma medicine used to treat adults with a particular type of asthma called eosinophilic asthma. It is…

read more

Positive CHMP opinion on the new medicine Juluca (dolutegravir / rilpivirine) for the treatment of HIV infection

On 22 March 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing…

read more


ELIXI International SA

Piazza Boffalora 4
6830 Chiasso / Switzerland

Tel: +41 91 682 20 40

Your name (required)

Your e-mail (required)

Your message